Important and inspiring tour de force The Francis Crick Institute lecture from Uğur Şahin. The age of mRNA therapies has arrived !

Amazing work, check it out! Congratulations Jon Lim, MRCP PhD and all in the Caetano Reis e Sousa

May is here, and so is VHL Awareness Month! Here's what's coming your way over the next few weeks: 🌟 Shareable social media content to educate and inspire. 🚶‍♀️ VHL Awareness Walk promo ahead of the big day on May 18th! 👋 Updates on what we're working on behind the scenes

🚨🚨 Register now for the 2024 Crick Cancer Research Symposium - awesome program of speakers highlighting recent advancements in our understanding of cancer. Abstract submissions close 06-SEP-2024 🚨🚨 tinyurl.com/ycxhnnja The Francis Crick Institute @TurajlicLab

Landmark decision by #NICE NHS England approving reimbursement of Belzutifan for management of VHL-related tumours. Wonderful news for patients and their carers; 1st approved systemic therapy for VHL! @vhl_uk_ireland VHL Alliance england.nhs.uk/2024/09/first-…

🤯 very cool

⭐️PhD opportunity alert ⭐️ Want to work in a fun, supportive environment targeting really novel models of melanoma metastasis? Pls retweet! crukcentre.manchester.ac.uk/opportunities/…

Phase 1 data on the HIF-2a inhibitor casdatifan presented by Toni Choueiri, MD at #ENASymp24. Among 86 pts with advanced solid tumors, the toxicity profile appeared favorable (mostly low grade anemia, fatigue, hypoxia), with an encouraging preliminary activity (ORR 25-34%). Dana-Farber

Great to contribute to this initiative and I look forward to the ongoing discussions. Many thanks to IKCC Kidney Cancer for sponsoring the event and to Grant Stewart and Axel Bex for organising

Excited to share our latest work. We introduce an improved version of NanoSeq, a duplex sequencing protocol with <5 errors per billion bp in single DNA molecules, and use it to study the somatic mutation landscape of oral epithelium in >1000 people. 1/n medrxiv.org/content/10.110…

As a farmer’s son and an oncologist here’s a review article I’m fully on board with - brilliant stuff!

Today is a very special day for patients with RCC : CHMP as approved BELZUTIFAN both for VHL disease associated RCC and for advanced renal cell carcinomas (following CPI and 2 VEGFR TKIs) Data presented at ESMO - Eur. Oncology and published in NEJM

Wonderful news for patients with VHL and sporadic RCC

Very excited to see publication of this personalised neoantigen vaccination in ccRCC in UK kidney cancer awareness week. Congratulations to the authors and look forward to the next steps of its clinical development

It’s unethical to test anything in humans without taking it to the full completion nytimes.com/2025/02/06/hea…

#IKCSEU25 and we’re off!

#IKCSEU25 great session on the promise of neoadjuvant Rx Zayd Tippu Leading the charge - excited for all the developments to come in the space ☄️

Very fortunate to work alongside such a talented bunch! The Royal Marsden NHS Foundation Trust renal unit @TurajlicLab representing at #IKCSEU25 👊🏼 ✌🏼 thanks for having us Kidney Cancer

I was very happy to present some of the updated data from LITESPARK-004 clinical trial at #IKCSEU25 - a great way to kick off #VHL awareness month !@VHLAlliance

JUST IN: 2 Belzutifan (HIF2 inhibitor) phase III trials POSTIVE for Primary Endpoint in Renal Cell Carcinoma: LITEPSPAK022 (adjuvant) + LITESPARK011 (metastatic, post PD1). BIG NEWS for GU Oncology + Kidney Cancer patients! tinyurl.com/2hywykhk tinyurl.com/mwawkbz7